×
About 19,503 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  6,833 results

Myelin loss in C9orf72 hexanucleotide expansion carriers.
https://doi.org/10.1002/jnr.25100
Journal of Neuroscience Research; Sirisi S, Querol-Vilaseca M et. al.

Jun 30th, 2022 - The most frequent genetic cause of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) is the hexanucleotide repeat expansion in C9orf72. An important neuropathological hallmark associated with this mutation is the acc...

An Expanded Access Protocol of RT001 in Amyotrophic Lateral Sclerosis-Initial Experienc...
https://doi.org/10.1002/mus.27672
Muscle & Nerve; Yerton M, Winter A et. al.

Jun 30th, 2022 - Lipid peroxidation is thought to play a biologically important role in motor neuron death in amyotrophic lateral sclerosis (ALS). 11,11 di-deuterated linoleic ethyl ester (RT001) prevents lipid peroxidation in cellular and mitochondrial membranes....

The progressive loss of brain network fingerprints in Amyotrophic Lateral Sclerosis pre...
https://doi.org/10.1016/j.nicl.2022.103095
NeuroImage. Clinical; Romano A, Trosi Lopez E et. al.

Jun 29th, 2022 - Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by functional connectivity alterations in both motor and extra-motor brain regions. Within the framework of network analysis, fingerprinting represents a reliable app...

Progestogen-mediated neuroprotection in central nervous system disorders.
https://doi.org/10.1159/000525677
Neuroendocrinology Bassani TB, Bartolomeo CS et. al.

Jun 28th, 2022 - Neuroactive steroids can be synthetic or endogenous molecules produced by neuronal and glial cells, and peripheral glands. Examples include estrogens, testosterone, progesterone and its reduced metabolites such as 5-dihydroprogesterone and allopr...

Feasibility, Acceptability, and Efficacy of Mindfulness Training in People with Upper M...
https://doi.org/10.1016/j.apmr.2022.05.020
Archives of Physical Medicine and Rehabilitation; Korupolu R, Malik A et. al.

Jun 28th, 2022 - This systematic review aims to gain a comprehensive understanding of the feasibility, acceptability, and efficacy of mindfulness-based interventions (MBIs) on depression, anxiety, fatigue, and health-related quality of life among individuals with ...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  538 results

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel TSPO Radioligand
https://clinicaltrials.gov/ct2/show/NCT03958630

Jun 24th, 2022 - Objectives The primary objective is to explore if human subjects with neurodegenerative diseases exhibit different level of neuroinflammation, as measured by brain uptake of a 3rd generation [11C]ER176 TSPO ligand, compared to control subjects. Th...

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
https://clinicaltrials.gov/ct2/show/NCT03225144

Jun 24th, 2022 - Objectives The primary objective is to evaluate patients referred with a diagnosis of frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), or related adult-onset neurodegenerative disorders to assess patient eligibility for ongoing ...

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT02437110

Jun 24th, 2022 - Objective: In this Phase I, proof-of-concept study, we aim to determine whether an antiretroviral regimen approved to treat human immunodeficiency virus (HIV) infection would also suppress levels of Human Endogenous Retrovirus-K (HERV-K) found to ...

Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
https://clinicaltrials.gov/ct2/show/NCT01925196

Jun 24th, 2022 - Objective The primary objective of this study is to characterize the natural history of disease in patients who carry a repeat expansion in the C9ORF72 gene, which causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The s...

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
https://clinicaltrials.gov/ct2/show/NCT04394871

Jun 24th, 2022 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...

see more →

News  395 results

FDA Unveils 5-Year Plan for ALS, Other Neurodegenerative Diseases
https://www.medscape.com/viewarticle/976169

Jun 24th, 2022 - The US Food and Drug Administration (FDA) has unveiled a 5-year strategy aimed at improving and extending the lives of people with rare neurodegenerative diseases. The agency's Action Plan for Rare Neurodegenerative Diseases including Amyotrophic ...

Tofersen linked to slow, positive effects in ALS
https://www.mdedge.com/neurology/article/255728/rare-diseases/tofersen-linked-slow-positive-effects-als
Kate Johnson

Jun 23rd, 2022 - An open-label extension of Biogen’s phase 3 VALOR study shows statistically significant benefits for the company’s novel antisense oligonucleotide (ASO), tofersen, in patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase.

Tofersen Linked to Slow but Positive ALS Outcomes
https://www.medscape.com/viewarticle/976134

Jun 23rd, 2022 - An open-label extension of Biogen's phase 3 VALOR study shows statistically significant benefits for the company's novel antisense oligonucleotide (ASO), tofersen, in patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase...

FDA Approves Oral Form of ALS Drug Edaravone
https://www.medscape.com/viewarticle/973926

May 13th, 2022 - The US Food and Drug Administration (FDA) has approved an orally administered version of edaravone (Radicava ORS) for adults with amyotrophic lateral sclerosis (ALS).  Edaravone is a pyrazolone free-radical scavenger thought to lessen the effects ...

Ultra-High Dose Drug Slows Functional Decline in Early ALS, Phase 3 Data Show
https://www.medscape.com/viewarticle/973901

May 12th, 2022 - An ultrahigh-dose of methylcobalamin slows functional decline by 43% in patients with early-stage amyotrophic lateral sclerosis (ALS), new research shows. The 50-mg dose was administered twice-weekly via intramuscular injection. In the phase 3 stu...

see more →

Patient Education  15 results see all →